Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for GreenSignal Bio Pharma IPO is 25. Their analysis recommends Do Not Subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 25 | Do Not Subscribe |
[Dilip Davda] This Company will enjoy first mover advantage in the important generic vaccine sector and will attract fancy going forward. Moderate investment may be considered for long term rewards as the issue size is small and will attract T segment listing for initial period due to which, short term rewards unlikely. Read detail review...
GreenSignal Bio Pharma IPO Reviews, analysis and views by popular members. Read GreenSignal Bio Pharma Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Note:
Useful Articles